Inclusion Criteria

• Patients confirmed Cushing's syndrome [i.e. ectopic corticotropin syndrome, adrenal adenoma, adrenal carcinoma, ACTH-Independent Macronodular Adrenal Hyperplasia (AIMAH), or Primary Pigmented Nodular Adrenal Dysplasia (PPNAD)]

• For patients on medical treatment for hypercortisolism due to Cushing's syndrome, the washout periods must be completed prior to baseline efficacy assessments.

Exclusion Criteria

• Patients with Cushing's disease

• History of hypersensitivity to osilodrostat or to drugs of similar chemical classes

• History of malignancy of any organ system, treated or untreated, within the past 5 years

• Patients receiving treatment for within 4 weeks or ≤5 x half-life of the agent (whichever is longer) before first dose of osilodrostat

• Patients with risk factors for QTc prolongation or Torsade de Pointes

• Other protocol defined Inclusion/Exclusion may apply.

Want to participate?

Pre-qualify now